Article

Laserex symposium addresses merits, mechanisms of SLT

Laserex held a breakfast symposium Sunday morning to address the merits and mechanisms of selective laser trabeculoplasty (SLT) and to provide a forum to discuss the efficacy of SLT in the treatment of open-angle glaucoma.

New Orleans-Laserex held a breakfast symposium Sunday morning to address the merits and mechanisms of selective laser trabeculoplasty (SLT) and to provide a forum to discuss the efficacy of SLT in the treatment of open-angle glaucoma.

Among the speakers were Prof. John Marshall, London; Ike Ahmed, MD, Canada; Alessandro Porta, MD, and Fabio Ferentini, MD, Italy; and Andrew Iwach, MD, United States.

Professor Marshall addressed the mechanisms of SLT. He expounded the biological response following SLT treatment, concentrating on the process in which the absorption of green light by the melanin containing cells with the trabecular meshwork stimulates the release of cytokines and triggers macrophage recruitment to clear the cells that have absorbed the light, thereby improving the circulation of aqueous through the trabeculum.

Dr. Ahmed discussed the merits of SLT and focused on the findings from several clinical trials based on measuring the efficacy of SLT as both a primary and adjunctive therapy. He indicated that SLT has been clinically proven to be as effective as argon laser trabeculoplasty for lowering IOP, and that SLT can be considered a primary treatment option for patients who cannot tolerate glaucoma medications.

In addition, Dr. Ahmed highlighted the efficacy of SLT as an adjunctive therapy when used in conjunction with glaucoma medications.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.